Phenotypes Associated with This Genotype

Genotype
MGI:4838433

• Allelic Composition: Stk39^tm1.2Slin/Stk39^tm1.2Slin
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

cardiovascular system

hypotension ( J:165706 )

homeostasis/metabolism

abnormal blood homeostasis ( J:165706 )

increased circulating aldosterone level ( J:165706 )

• secondary hyperaldosteronism

decreased circulating magnesium level ( J:165706 )

decreased circulating potassium level ( J:165706 )

• decreased plasma potassium ion concentration

decreased urine chloride ion level ( J:165706 )

• decreased fractional excretion of chloride ion after hydrochlorothiazide treatment

increased urine potassium level ( J:165706 )

• increased fractional excretion of potassium

decreased urine sodium level ( J:165706 )

• fractional excretion decreased significantly after hydrochlorothiazide treatment

decreased urine calcium level ( J:165706 )

increased urine magnesium level ( J:165706 )

• increased fractional excretion of magnesium ion

renal/urinary system

decreased urine chloride ion level ( J:165706 )

• decreased fractional excretion of chloride ion after hydrochlorothiazide treatment

increased urine potassium level ( J:165706 )

• increased fractional excretion of potassium

decreased urine sodium level ( J:165706 )

• fractional excretion decreased significantly after hydrochlorothiazide treatment

decreased urine calcium level ( J:165706 )

increased urine magnesium level ( J:165706 )

• increased fractional excretion of magnesium ion

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
Gitelman syndrome		DOID:0050450	OMIM:263800	J:165706